The opportunity in biopharmaceuticals is big and growing too rapidly to ignore. Today, biopharmaceuticals generate global revenues of approximately $163 billion, making up about 20 percent of the pharma market. It’s certainly a fast-growing part of the industry: biopharma’s current annual growth rate of more than 8 percent is double that of conventional pharma, and growth is expected to continue at that rate for the foreseeable future.
The efficacy and safety of biopharmaceutical products, combined with their ability to address previously un-treatable conditions, allows pharma companies to command high prices for innovative drugs. Strong demand has driven significant profits, despite the high cost of goods sold. Biopharmaceuticals have set new standards for blockbuster drugs as well. Blockbusters are traditionally defined as drugs that have $1 billion or more in annual sales; the top 15 biopharma products each enjoy annual revenue of more than $2 billion, with some, such as the anti-inflammatory drug Humira, generating sales of more than $10 billion a year. For many players, the biggest challenge has been simply making enough product to sell. It’s no surprise that major pharmaceutical companies around the world are increasingly shifting their R&D and sourcing focus to large-molecule products, hence the positioning and opportunity our C1 program can support with.
According to a study published by Global Biosimilar Market Outlook 2020 Biologic drugs, which includes antibodies, are the fastest growing drug segment
- In 2014, biologics accounted for 21% of total global spending on medicines
- Biologic spending are expected to grow at 10.1% CAGR until 2020 to $287 billion
- The global biosimilar market is growing due to the need for lower cost biologics
- $1.9B market in 2014 is expected to reach $25.5B by 2020, growing at an impressive CAGR of 54.4%
- Increasingly greater drug pricing pressures along with competition for biosimilars is expected to reduce drug pricing by 45% or more
Governments of various countries are involved in taking initiatives for improving healthcare facilities, and making next-generation antibody therapeutics affordable. This is increasing the demand for next-generation antibody therapeutics. The increasing global gross domestic product (GDP) and growing healthcare expenditure have created a positive impact on the growth of the next-generation antibody therapeutics market. Also, in comparison to traditional antibodies, the next-generation antibody therapeutics are promising to be more effective in the treatment of various diseases, such as cancer, autoimmune disorders, and inflammatory diseases. This is attracting various pharmaceutical and biotechnology companies to increase their investment in the R&D of next-generation antibody therapeutics.
New technologies like Dyadic’s C1 technology have the potential to provide the pharmaceutical industry with a way to insure patient access and affordability to biologic drugs while helping the industry maintain profitability.
We believe the C1 technology has the potential to:
- Lower the costs of biologics
- Help bring new and improved biologics to market
- Help to overcome protein expression challenges of potential biologics stuck in R&D
With the rapid growth in the biologics market there is increasing pressure on global health care systems to reduce costs. Dyadic believes that its C1 technology has the potential to be a safe and efficient expression system that can help speed up the development and production of antibodies at flexible commercial scales. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes C1 can potentially help bring biologic vaccines and drugs to market faster, in greater volumes and at lower cost to drug developers and manufacturers. This can potentially improve access and reduce costs to patients and the healthcare system, and most importantly save lives.